Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SWI and T2*-GRE Microhemorrhage Counts in Anti-Amyloid Therapy Eligibility: A Real-World-Calibrated Simulation Study.

medRxiv : the preprint server for health sciences·2026
Same author

Study partner profile effects on CDR-SB change in anti-amyloid therapy evaluation.

medRxiv : the preprint server for health sciences·2026
Same author

Potential and biases of large language model simulation for public surveys on Alzheimer's disease therapies.

Journal of Alzheimer's disease : JAD·2026
Same author

Provider and patient perspectives on the diagnosis and treatment of Alzheimer's disease: A global perspective from the Global Alzheimer's Leadership Series (GoALS).

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Mapping U.S. POINTER Cognitive-Slope Gains Onto Predicted Clinical Progression: An External-Cohort Translation Analysis With Exploratory Economic Thresholds.

medRxiv : the preprint server for health sciences·2026
Same author

Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Takeshi Iwatsubo1

  • 1Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary

Plasma tau phosphorylated at threonine 217 (p-tau217) and Aβ biomarkers accurately predict amyloid PET positivity in early Alzheimer's disease (AD). These blood tests can help screen patients for clinical trials and monitor treatment effectiveness.

Area of Science:

  • Neurology
  • Biomarker Discovery
  • Alzheimer's Disease Research

Background:

  • Urgent need for plasma biomarkers to predict amyloid PET positivity in early Alzheimer's disease (AD).
  • Evaluating the utility of plasma tau phosphorylated at threonine 217 (p-tau217) for predicting amyloid PET status.
  • Assessing the role of plasma biomarkers in monitoring disease-modifying therapies (DMTs) for AD.

Purpose of the Study:

  • Determine the accuracy of plasma p-tau217 and Aβ biomarkers in predicting amyloid PET positivity.
  • Investigate the combined utility of plasma biomarkers and clinical information for predicting Aβ-PET status.
  • Assess the potential of plasma biomarkers for prescreening patients and monitoring DMT efficacy in AD.

Main Methods:

  • Utilized the Japanese trial-ready cohort for preclinical/prodromal AD (J-TRC) with 474 non-demented individuals.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699
  • Assessed participants using amyloid PET (florbetapir or flutemetamol) and plasma biomarker assays (p-tau217, Aβ42, Aβ40).
  • Measured plasma biomarkers using IP mass spectrometry and immunoassay platforms.

    • Main Results:

    • Plasma p-tau217 demonstrated high accuracy (AUC = 0.913) in detecting abnormal Aβ-PET scans.
    • Plasma Aβ42/40 ratio also showed high accuracy (AUC = 0.856) in predicting Aβ-PET positivity.
    • Models combining plasma biomarkers (p-tau217/Aβ42 ratio) with clinical information (APOE, age, sex) achieved the highest AUCs (up to 0.955).

    Conclusions:

    • Plasma p-tau217 alone or in combination with Aβ biomarkers effectively predicts Aβ-PET positivity in preclinical and prodromal AD.
    • Plasma p-tau217 assays show promise for prescreening patients for clinical trials.
    • The utility of these plasma assays for monitoring anti-Aβ antibody and other DMT efficacy is under evaluation in real-world settings.